PROV-MESH: Prophylactic Ovarian Cancer MESH
Eligible age
18+ yrs
Accepts
Women
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Incisional hernia is a common complication after midline laparotomy and may significantly impact quality of life, morbidity, and healthcare costs. Patients undergoing cytoreductive surgery for ovarian cancer are considered at increased risk due to extensive surgical procedures, nutritional status, and exposure to systemic treatments. This prospective randomized clinical trial aims to evaluate whether prophylactic mesh placement during abdominal wall closure reduces the incidence of incisional hernia compared with conventional fascial closure in women undergoing cytoreductive surgery for ovarian cancer through a midline laparotomy. To control for the potential effect of negative pressure wound therapy (NPWT) on surgical site infection, participants will also be randomized to receive NPWT or standard wound dressing, resulting in four treatment arms.
Sponsor: Hospital Vall d'Hebron
You may qualify if…
- ✓ Female patients diagnosed with ovarian carcinoma.
- ✓ Undergoing primary cytoreductive surgery, interval cytoreductive surgery, or delayed cytoreductive surgery after six cycles of chemotherapy.
- ✓ Surgical procedure performed through a midline laparotomy.
- ✓ Ability and willingness to provide written informed consent.
You may not qualify if…
- ✕ Surgery for recurrent ovarian cancer (secondary, tertiary, or subsequent cytoreductions).
- ✕ Minimally invasive surgical approach.
- ✕ Planned secondary cytoreductive surgery during the 24-month follow-up period.
- ✕ Inability or unwillingness to comply with follow-up requirements.
Source: ClinicalTrials.gov · NCT07676370 · last updated 2026-06-30